Pentraxin 3,Human,ELISA Kit

Product#: PP-PD03-E0
$1,385.00
Availability:
Ships in 1-2 weeks

Pentraxin 3,Human,ELISA Kit <TSG-14,ELISA System>

DiagnoCine offers excellent TSG-14 | PTX3 | Pentaxin3 antibodies and ELISA  for researchers studying inflammatory cytokines, inflammation stimuli, Immune-response in mesenchymal, epithelial cells, endothelial cells, and mononuclear phagocytes | fibrocyte differentiation, regulation pathways in inflammation and complement activation | regulation of innate resistance to pathogens, clearance of self-components and female fertility | association with virion binding and (1->3)-beta-D-glucan binding.

Human diseases include Infectious Myocarditis, Takayasu Arteritis, Innate Immune System, and Lung Fibrosis.

TSG-14 | PTX3 | Pentaxin3 antibodies  have excellent quality and this highly pure antibody can be adapted for Western Blots, ELISA, Immunohistochemistry, Immunofluorescence research with optimization. 

Cat. No. PP-PD03-E0
Size 1 Kit
Storage 4°C

Description

Pentraxin 3 (PTX3), also known as tumor necrosis factor-stimulated gene sequence-14 (TSG-14), is categorized in Long Pentraxin among Pentraxin family which is a member of inflammatory protein such as CRP and SAP.

PTX3 is secreted by vascular endothelial cells, macrophages, fibroblasts and smooth muscle cells in response to inflammatory signals like LPS, IL-1 and TNF. PTX3 is a potential biomarker of Myocardial Infarction and Atherosclerosis.

Immunosorbent assay for the quantitative measurement of human Pentraxin3(PTX3) in plasma and serum-free cell culture supernatant

Perseus Proteomics have established a high sensitivity PTX3 detection method, which we expect to be a breakthrough biomarker capable of predicting patients' risk of atherosclerosis in the earliest stages. 

We start selling our high sensitivity PTX3 ELISA kit “Human Pentraxin 3 / TSG-14 ELISA System” for research use only. 

Specification

  • Species : Human
  • Assay Range : 0.5 - 20 ng/mL
  • Sensitivity : 0.1 ng/mL
  • Sample : EDTA plasma, FBS-free Cell culture supernatants
  • Average recovery : 97.3%
  • Cross reactivity with CRP and SAP : < 0.1 ng/mL

Kit Components

  • Anti-human PTX3 antibody precoated strip well plate, 1 (96 well)
  • HRP conjugated anti-PTX3 antibody reagent, 1 vial (12 mL)
  • Human PTX3 standards 0, 0.5, 1.0, 2.5, 5.0, 10, 20 ng/mL, 7 vials (0.1 mL)
  • 10X Wash buffer concentrate, 1 vial (100 mL)
  • Dilution buffer, 1 vial (15 mL) containing preservative
  • TMB solution, 1 vial (12 mL)
  • Stop solution, 1 vial (12 mL)
  • Adhesive plate covers, 3 sheets
  • Instruction manual

Assay Protocol

PP-PD03-E0_fig1-1.jpg

Sample preparation

  • Plasma
Fresh or defrosted human plasma prepared with EDTA. Samples may be stored at <−20℃.
After collecting blood, centrifuge for 10 minutes at 3,000 rpm. Assay immediately or aliquot and store samples at <−20℃ within 2 hours.
Caution: Serum, heparin plasma and citrate plasma samples can NOT be used with this kit.
  • Cell culture supernatants
Remove particulates by centrifugation and assay immediately or aliquot and store samples at <−20℃.
Caution
Using culture supernatant containing serum (FBS) is not recommended, as there is some possibility of assay inhibition by FBS. If you use culture supernatant containing FBS, please verify recovery prior to measuring samples.


Performance cheracteristics --Lineality and Detection limit --

Lineality and Detection limit :
Representative calibration curve based on PTX3 calibrators of 0.5-20ng/mL. The lower limit of detection is 0.1ng/mL

Performance cheracteristics --Spike and Recovery--

Average recovery is 97.3.

Performance cheracteristics --Cross reactivity--

PP-PD03-E0_fig2-1.jpg
 
Cross reactivity with CRP and SAP is <0.1ng/mL, Cross reactivity test


Performance cheracteristics --Reproducibility--

PP-PD03-E0_fig3-1.jpg
 Intra-assay within 4.1%, Inter-assay within 4.3%, Intra-assay and Inter-assay

Publications / Citations

  1. Arterioscler Thromb Vasc Biol. 2007 ; 27(1) : 161-7.  Inoue K et al.
  2. Clin J Am Soc Nephrol. 2007 ; 2(5) : 889-97. Tong M et al. 
  3. Cell Immunol. 2007 ; 248(2) : 86-94. Imamura M et al.
  4. J Pathol. 2008 ; 215(1) : 48-55.  Savchenko A et al.
  5. Atherosclerosis 2008 ; 197(1) : 368-74 Kotooka N et al., Inoue T et al.
  6. Am Heart J. 2008 ; 155(1) : 75-81. Suzuki S et al.
  7. Dig Dis Sci. 2008 ; 53(7) : 1910-6. Kato S et al.
  8. Int J Cardiol. 2008 ; 130(1) : 19-22. Kotooka N et al.
  9. Clin Chem Lab Med. 2009 ; 47(4) : 471-7.  Yamasaki K et al.
  10. Journal of Analytical Bio-Science 2010 ; 33(4) : 289-97 Inoue K. et al.
  11. Journal of Analytical Bio-Science 2010 ; 33(4) : 298-306 Yamaguchi N. et al.
  12. Journal of Analytical Bio-Science 2010 ; 33(4) : 307-12 Kotooka N.
  13. Journal of Analytical Bio-Science 2010 ; 33(4) : 313-20 Maemura K et al.
  14. Journal of Analytical Bio-Science 2010 ; 33(4) : 321-8 Kato S et al.
  15. Journal of Analytical Bio-Science 2010 ; 33(4) : 329-38 Naito M et al.
  16. Journal of Analytical Bio-Science 2010 ; 33(4) : 339-46 Ogawa T et al.
  17. Journal of Analytical Bio-Science 2010 ; 33(4) : 347-54 Hatakeyama K et al. 
  18. Clin J Am Soc Nephrol. 2014 ; 9(7) : 1207-16 Yilmaz MI et al.

 


Logo_ppmx.gif

Satisfaction
Quality Rating
Value Rating
Style Rating
X